Clinical Trial Update: A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation [Phase 1]

View source ↗

Summary

A Phase 1 study of PRT7732, an oral SMARCA2 degrader, in patients with SMARCA4-mutant advanced or metastatic solid tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Esophageal Cancer
• Esophageal Squamous Cell Carcinoma
• Gastric Adenocarcinoma
• Gastric Cancer
• Gastric Squamous Cell Carcinoma
• Gastroesophageal Junction Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• PRT7732

Snippet

Sponsor: Prelude Therapeutics | Conditions: Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Status: TERMINATED